文献速递神经核医学核素与放射性配体治疗

弥漫性内生性桥脑胶质瘤患者瘤内对流增强递送124I-omburtamab的诊疗一体研究:药代动力学与病灶剂量测定

Theranostic Intratumoral Convection-Enhanced Delivery of 124I-Omburtamab in Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion Dosimetry.
PubMed 文献 · J Nucl Med · 2024-09-03

本研究为首次人体试点研究,45例弥漫性内生性桥脑胶质瘤(DIPG)患者经对流增强递送(CED)瘤内注射9.0-370.7 MBq的124I-omburtamab,行系列PET/CT及血样动力学分析。结果显示病灶内放射性滞留数天,病灶剂量当量353±181 mSv/MBq,全身剂量低(0.69±0.28 mSv/MBq),血液剂量0.27±0.21 mGy/MBq,作者认为该诊疗一体方法可将高辐射剂量递送至DIPG病灶并具有较宽的安全边界。

要点

  • 45例DIPG患者经CED瘤内注射124I-omburtamab,病灶内活性滞留数天,平均124I驻留时间24.9 h。
  • 病灶剂量当量353±181 mSv/MBq,全身剂量当量0.69±0.28 mSv/MBq,血液剂量0.27±0.21 mGy/MBq。
  • 全身清除呈单指数,平均生物半衰期62.7 h,有效半衰期37.9 h。

核心结论

  • 瘤内CED递送124I-omburtamab是DIPG的一种新型诊疗一体方法,可将高辐射剂量递送至DIPG病灶,病灶活性高、全身活性低、肿瘤与正常组织比值高,并达到较宽的安全边界。
  • 对实际治疗给药的124I-omburtamab进行显像,可直接估算治疗性病灶和正常组织的吸收剂量。

研究设计与样本

  • 首次人体试点研究,45例DIPG患者经CED瘤内注射9.0-370.7 MBq的124I-omburtamab。
  • 注射结束后4、24-48、72-96、120-144、168-240 h内3-5个时间点行系列脑部及全身PET/CT显像。
  • 采集系列血样进行动力学分析,测量全身、血液、病灶及正常组织活性,估算摄取与清除半衰期等动力学参数,并使用OLINDA软件计算辐射吸收剂量。

主要发现

  • 所有患者病灶内均显示显著活性,并滞留数天,可检测至末次显像时间点,病灶平均124I驻留时间24.9 h,剂量当量353±181 mSv/MBq。
  • 全身剂量低,剂量当量0.69±0.28 mSv/MBq;正常器官及血液的系统分布和活性低。
  • 血液辐射剂量很低,平均0.27±0.21 mGy/MBq。
  • 全身清除呈单指数,平均生物半衰期62.7 h,有效半衰期37.9 h。
  • 血液清除呈双指数,快速α相平均生物半衰期22.2 h,较慢β相155 h。

临床怎么用

  • 作者认为瘤内CED递送124I-omburtamab是DIPG的一种新型诊疗一体方法,可递送高辐射剂量至DIPG病灶并具有较宽的安全边界。
  • 作者指出对实际治疗给药的124I-omburtamab进行显像可直接估算治疗性病灶和正常组织的吸收剂量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse intrinsic pontine glioma (DIPG) is a rare childhood malignancy with poor prognosis. There are no effective treatment options other than external beam therapy. We conducted a pilot, first-in-human study using 124I-omburtamab imaging and theranostics as a therapeutic approach using a localized convection-enhanced delivery (CED) technique for administering radiolabeled antibody. We report the detailed pharmacokinetics and dosimetry results of intratumoral delivery of 124I-omburtamab. Methods: Forty-five DIPG patients who received 9.0-370.7 MBq of 124I-omburtamab intratumorally via CED underwent serial brain and whole-body PET/CT imaging at 3-5 time points after injection within 4, 24-48, 72-96, 120-144, and 168-240 h from the end of infusion. Serial blood samples were obtained for kinetic analysis. Whole-body, blood, lesion, and normal-tissue activities were measured, kinetic parameters (uptake and clearance half-life times) estimated, and radiation-absorbed doses calculated using the OLINDA software program. Results: All patients showed prominent activity within the lesion that was retained over several days and was detectable up to the last time point of imaging, with a mean 124I residence time in the lesion of 24.9 h and dose equivalent of 353 ± 181 mSv/MBq. Whole-body doses were low, with a dose equivalent of 0.69 ± 0.28 mSv/MBq. Systemic distribution and activities in normal organs and blood were low. Radiation dose to blood was very low, with a mean value of 0.27 ± 0.21 mGy/MBq. Whole-body clearance was monoexponential with a mean biologic half-life of 62.7 h and an effective half-life of 37.9 h. Blood clearance was biexponential, with a mean biologic half-life of 22.2 h for the rapid α phase and 155 h for the slower β phase. Conclusion: Intratumoral CED of 124I-omburtamab is a novel theranostics approach in DIPG. It allows for delivery of high radiation doses to the DIPG lesions, with high lesion activities and low systemic activities and high tumor-to-normal-tissue ratios and achieving a wide safety margin. Imaging of the actual therapeutic administration of 124I-omburtamab allows for direct estimation of the therapeutic lesion and normal-tissue-absorbed doses.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Pandit-Taskar N, Zanzonico PB, Grkovski M, et al. Theranostic Intratumoral Convection-Enhanced Delivery of 124I-Omburtamab in Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion Dosimetry. J Nucl Med. 2024. PMID: 39142829. doi:10.2967/jnumed.123.266365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。